- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | NASDAQ warnt Ernexa Therapeutics vor Delisting wegen niedrigem Aktienkurs | 2 | Investing.com Deutsch | ||
| Fr | Ernexa Therapeutics Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 13.03. | Ernexa Therapeutics Inc. - 10-K, Annual Report | 2 | SEC Filings | ||
| 26.02. | Ernexa Therapeutics Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 20.02. | Ernexa Therapeutics Inc.: Ernexa Therapeutics to Participate in Virtual Investor Closing Bell Series | 1 | GlobeNewswire (USA) | ||
| 11.02. | Ernexa Therapeutics Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 06.02. | Ernexa Therapeutics Inc.: Ernexa Therapeutics Announces Pricing of $10.5 Million Public Offering | 177 | GlobeNewswire (Europe) | CAMBRIDGE, Mass., Feb. 06, 2026 (GLOBE NEWSWIRE) -- Ernexa Therapeutics Inc. (Nasdaq: ERNA) ("Ernexa" or the "Company"), an industry innovator developing novel cell therapies for the treatment of... ► Artikel lesen | |
| 05.02. | Ernexa Therapeutics Inc. - 8-A12B, Registration of securities | 1 | SEC Filings | ||
| ERNEXA THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 04.02. | Ernexa Therapeutics Inc. - S-1/A, General form for registration of securities | - | SEC Filings | ||
| 03.02. | Ernexa Therapeutics Inc.: Ernexa Therapeutics Participates in Virtual Investor "What This Means" Segment Highlighting Recent Successful Pre-IND Meeting with U.S. FDA | 1 | GlobeNewswire (USA) | ||
| 27.01. | Ernexa Therapeutics Inc.: Ernexa Therapeutics Selected as One of Only Ten Global Companies for Prestigious JETRO Japan Entry Acceleration Program | 1 | GlobeNewswire (USA) | ||
| 06.01. | Ernexa Therapeutics Inc.: Ernexa Therapeutics Announces Successful Pre-IND FDA Meeting and Continues Progress Toward First-in-Human Trial in Ovarian Cancer | 1 | GlobeNewswire (USA) | ||
| 11.12.25 | Ernexa Therapeutics Inc. - 8-K, Current Report | - | SEC Filings | ||
| 08.12.25 | Ernexa Therapeutics: Aktie fällt trotz positiver Studiendaten | 2 | Investing.com Deutsch | ||
| 08.12.25 | Ernexa Therapeutics Inc.: Ernexa Therapeutics Presents New Preclinical Data at American Society of Hematology (ASH) Annual Meeting on Lead Cell Therapy Candidate for Treatment of Ovarian Cancer | 1 | GlobeNewswire (USA) | ||
| 03.12.25 | Ernexa Therapeutics Inc.: Ernexa Therapeutics Announces Oral Presentation at the 67th American Society of Hematology (ASH) Annual Meeting | 1 | GlobeNewswire (USA) | ||
| 02.12.25 | Ernexa Therapeutics appoints oncologist Dr. Winer to advisory board | 1 | Investing.com | ||
| 02.12.25 | Ernexa Therapeutics Inc.: Ernexa Therapeutics Strengthens Scientific and Medical Advisory Board with Appointment of Leading Oncologist Dr. Ira S. Winer, M.D., Ph.D., FACOG | 1 | GlobeNewswire (USA) | ||
| 11.11.25 | Ernexa Therapeutics Inc.: Ernexa Therapeutics to Present at Oxford Global's Cell 2025 | 2 | GlobeNewswire (USA) | ||
| 10.11.25 | Eterna Therapeutics reports Q3 results | 1 | Seeking Alpha |
1 2 Weiter >>
36 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIOAFFINITY TECHNOLOGIES | 4,750 | 0,00 % | What's Going On With bioAffinity Stock Thursday? | ||
| APOGEE THERAPEUTICS | 79,16 | 0,00 % | Morning Market Movers: urban-gro, WeShop Holdings, QVC Group, Apogee Therapeutics See Big Swings | OTTAWA (dpa-AFX) - At 8:30 a.m. ET on Monday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| QIAGEN | 34,145 | -0,29 % | QIAGEN N.V.: Qiagen Announces Form 20-F Annual Report Filing for 2025 Results | QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that it has filed its annual report, including its audited consolidated financial statements on Form 20-F, for the year ended... ► Artikel lesen | |
| CG ONCOLOGY | 64,92 | 0,00 % | CG Oncology Inc.: CG Oncology Reports 2025 Year End Financial Results and Provides Business Updates | PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy as an adjuvant therapy in intermediate-risk NMIBC expected first half 2026CORE-008 Cohort CX Phase 2 first results of combination... ► Artikel lesen | |
| VERA THERAPEUTICS | 40,750 | 0,00 % | Vera Therapeutics Announces Appointment of Matt Skelton to Chief Commercial Officer | BRISBANE, Calif., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments... ► Artikel lesen | |
| ERASCA | 14,310 | 0,00 % | Erasca (ERAS) Adds 13%; Soars 310% YTD | ||
| ARCELLX | 114,61 | 0,00 % | Laufende Fusionskontrollverfahren: Gilead Sciences, Foster City, CA/USA; Erwerb sämtlicher Anteile an und Kontrolle über die Arcellx, Redwood City, CA/USA | Datum der Anmeldung:13.03.2026Aktenzeichen:B3-41/26Unternehmen:Gilead Sciences, Foster City, CA/USA; Erwerb sämtlicher Anteile an und Kontrolle über die Arcellx, Redwood City, CA/USAProduktmärkte:Hämatologie... ► Artikel lesen | |
| ADMA BIOLOGICS | 13,570 | 0,00 % | ADMA Biologics Announces $200 Mln Capital Return Plan | ||
| PRAXIS PRECISION MEDICINES | 293,87 | 0,00 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full-Year 2025 Financial Results | Two new drug applications (NDA) for ulixacaltamide in essential tremor (ET) and for relutrigine in SCN2A and SCN8A developmental and epileptic encephalopathies (DEEs) have been submitted to the U.S.... ► Artikel lesen | |
| TYRA BIOSCIENCES | 36,500 | 0,00 % | Tyra Biosciences Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Highlights | - Launched "dabogratinib 3x3" strategy to pursue 3 late-stage clinical studies in LG-UTUC, IR NMIBC and ACH, 3 potential blockbuster indications -
- Interim Ph2... ► Artikel lesen | |
| BIONTECH | 75,00 | -2,72 % | BioNTech SE: BioNTech auf dem ELCC-Kongress 2026: Neue klinische Daten unterstreichen das Potenzial des differenzierten, spätklinischen Portfolios bei Lungenkrebs | Präsentationen zeigen Fortschritte in BioNTechs spätklinischen Programmen im Bereich Lungenkrebs und unterstreichen das Potenzial des differenzierten Unternehmensportfolios, welches Immunmodulatoren... ► Artikel lesen | |
| COGENT BIOSCIENCES | 35,400 | 0,00 % | Cogent Biosciences, Inc.: Cogent Biosciences Highlights Additional Data with Six Bezuclastinib Posters from SUMMIT Trial at 2026 AAAAI Annual Meeting | Bezuclastinib mean TSS reduction deepens to -32.0 points at 48 weeks of treatment with further improvement shown across all measured symptoms99% of patients achieve >50% reduction in serum tryptase... ► Artikel lesen | |
| VALNEVA | 2,926 | -35,27 % | Valneva: Nettoverlust wegen Sondereffekt vervielfacht - Lyme-Daten entscheidend | Der Impfstoffhersteller Valneva hat im Geschäftsjahr 2025 einen Nettoverlust von 115,2 Millionen Euro ausgewiesen, nach einem Verlust von 12,2 Millionen Euro im Vorjahr. Der Vergleich ist jedoch durch... ► Artikel lesen | |
| STRUCTURE THERAPEUTICS | 49,080 | 0,00 % | Citizens reiterates Structure Therapeutics stock rating on weight loss data | ||
| ALUMIS | 23,370 | 0,00 % | Alumis Inc.: Alumis Reports Year End 2025 Financial Results and Highlights Recent Achievements | - Positive Phase 3 topline results demonstrating envudeucitinib's leading skin clearance, meaningful symptom improvement and a favorable safety profile in patients with moderate-to-severe plaque psoriasis... ► Artikel lesen |
ERNEXA THERAPEUTICS INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 0,237 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ERNEXA THERAPEUTICS INC finden Sie auf Wallstreet Online.